These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGF-receptor kinase inhibitors. Verheul HM; Pinedo HM Clin Breast Cancer; 2000 Sep; 1 Suppl 1():S80-4. PubMed ID: 11970755 [TBL] [Abstract][Full Text] [Related]
28. Up-regulation of flk-1/vascular endothelial growth factor receptor 2 by its ligand in a cerebral slice culture system. Kremer C; Breier G; Risau W; Plate KH Cancer Res; 1997 Sep; 57(17):3852-9. PubMed ID: 9288799 [TBL] [Abstract][Full Text] [Related]
30. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522 [TBL] [Abstract][Full Text] [Related]
31. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Bunone G; Vigneri P; Mariani L; Butó S; Collini P; Pilotti S; Pierotti MA; Bongarzone I Am J Pathol; 1999 Dec; 155(6):1967-76. PubMed ID: 10595926 [TBL] [Abstract][Full Text] [Related]
32. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells. Yoshiji H; Kuriyama S; Hicklin DJ; Huber J; Yoshii J; Miyamoto Y; Kawata M; Ikenaka Y; Nakatani T; Tsujinoue H; Fukui H Hepatology; 1999 Nov; 30(5):1179-86. PubMed ID: 10534339 [TBL] [Abstract][Full Text] [Related]
33. Angiogenesis inhibitors: a rational strategy for radiosensitization in the treatment of non-small-cell lung cancer? Raben D; Helfrich B Clin Lung Cancer; 2004 Jul; 6(1):48-57. PubMed ID: 15310417 [TBL] [Abstract][Full Text] [Related]
34. VEGF-VEGFR System as a Target for Suppressing Inflammation and other Diseases. Shibuya M Endocr Metab Immune Disord Drug Targets; 2015; 15(2):135-44. PubMed ID: 25772179 [TBL] [Abstract][Full Text] [Related]
36. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Takahashi H; Shibuya M Clin Sci (Lond); 2005 Sep; 109(3):227-41. PubMed ID: 16104843 [TBL] [Abstract][Full Text] [Related]
37. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic. Epstein RJ Cancer Metastasis Rev; 2007 Dec; 26(3-4):443-52. PubMed ID: 17786538 [TBL] [Abstract][Full Text] [Related]
38. [VEGF as an angiogenic, neurotrophic, and neuroprotective factor]. Namiecińska M; Marciniak K; Nowak JZ Postepy Hig Med Dosw (Online); 2005; 59():573-83. PubMed ID: 16407796 [TBL] [Abstract][Full Text] [Related]
39. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Vacca A; Ria R; Ribatti D; Semeraro F; Djonov V; Di Raimondo F; Dammacco F Haematologica; 2003 Feb; 88(2):176-85. PubMed ID: 12604407 [TBL] [Abstract][Full Text] [Related]
40. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro. Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]